Stock analysts at BMO Capital Markets lifted their price objective on shares of Valeant Pharmaceuticals (NYSE:VRX) from $132.00 to $146.00 in a report issued on Wednesday, Analyst RN reports. BMO Capital Markets’ price objective would suggest a potential upside of 16.47% from the company’s current price. Shares of Valeant Pharmaceuticals (NYSE:VRX) opened at 125.35 on […]
Valeant Pharmaceuticals Price Target Raised to $146.00 at BMO Capital Markets (VRX) is a post from: Zolmax
The post Valeant Pharmaceuticals Price Target Raised to $146.00 at BMO Capital Markets (VRX) appeared first on Zolmax.